Dimerix eyes accelerated approval for rare kidney disease drug Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 8 October, 2025

sponsored by Making complex cell therapies more cost-effective to scale. A must-read roadmap for global biotech leadership. Informed by an international workshop, the report outlines 11 priority actions to scale cell therapies from 100s to 10,000s of doses per year. Cutting through the complexity of process translation, discover how industry insiders are proposing to move the needle in constructive collaboration, automation, digitalisation, and business model innovation. Read the full report now

presented by The on­ly met­ric that mat­ters: en­roll­ment. How in­sid­ers on­ly pay for dosed pa­tients.

SPOTLIGHT Meet 20 women reshaping biopharma, from early discovery to patient advocacy •  Biopharma makes little progress on gender diversity, as women make up 11% of CEO ranks

news Sanofi and radioligand partner Orano Med report mid-stage win in rare tumor In $2B biobucks pact, Zenas snags MS drug that Biogen returned to InnoCare Dimerix says observational analysis could back speedier path to market for rare kidney disease drug Post-Hoc Live: Vijay Pande on what's next after a16z, his outlook of AI in bio Lilly hires ex-CBER chief Marks, who is focusing on molecule discovery and infectious diseases

Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

ESMO 2025 will deliver pivotal cancer trial data. Join Endpoints for strategic analysis of what matters most. Register now.

ENDPOINTS PHARMA FDA approves Boehringer Ingelheim’s idiopathic pulmonary fibrosis pill GLP-1 coverage update from CMS coming 'very soon,' Oz says Third Circuit appeals court tosses Novo Nordisk’s IRA case  Eli Lilly earmarks $1B to boost India manufacturing footprint

in case you missed it 1. Soufflé Therapeutics, co-founded by Bob Langer, launches with $200M 2. Mark Alles’ biotech gets $96M for ADCs from UCLA lab 3. Lexeo eyes faster path to approval for Friedreich's ataxia gene therapy 4. News Briefing Adicet reveals Phase 1 data for lupus therapy; Arcus’ ‘best-in-class’ kidney cancer drug 5. MapLight eyes $227M IPO as biopharma market warms up 6. AstraZeneca’s hypertension pill scores second late-stage win